1. Increasing awareness and acceptance of Preimplantation Genetic Testing (PGT) among individuals seeking assisted reproductive technologies.
2. Technological advancements leading to the development of new and more efficient PGT techniques.
3. Rising prevalence of genetic disorders and chromosomal abnormalities driving the demand for PGT services.
Industry
Report Coverage | Details |
---|---|
Segments Covered | Procedure, Product, Technology, Application, End-Use |
Regions Covered | • North America (United States, Canada, Mexico) • Europe (Germany, United Kingdom, France, Italy, Spain, Rest of Europe) • Asia Pacific (China, Japan, South Korea, Singapore, India, Australia, Rest of APAC) • Latin America (Argentina, Brazil, Rest of South America) • Middle East & Africa (GCC, South Africa, Rest of MEA) |
Company Profiled | Quest Diagnostics Incorporated, Natera,, COOPER SURGICAL, INC., Genea Pty Limited., Invitae, Laboratory of America Holdings, Thermo Fisher Scientific, Bioarray S.L., Illumina,, Igenomix, RGI, F. Hoffmann-La Roche |
1. High cost associated with PGT procedures limiting access for a significant portion of the population.
2. Ethical and regulatory concerns surrounding the use of PGT technology, leading to potential restrictions on its widespread adoption.